Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
RMD Open 2024;12:e004476 doi: 10.1136/rmdopen-2024-004476
Buch et al. demonstrated that filgotinib sustained its efficacy in rheumatoid arthritis patients through Wk156 in the FINCH 4 long-term extension study, showing stable safety profiles. The study reported high ACR response rates and remission based on Boolean criteria, underlining filgotinib's potential for extended clinical benefits.
The analysis included 2,729 participants receiving either de novo or continued filgotinib treatment, focusing on achieving remission and low disease activity. The study primarily evaluated long-term safety and efficacy, confirming the drug’s tolerability and enduring effectiveness in rheumatoid arthritis treatment.
Keywords:
